DE3719398C2 - Liganden und deren Verwendung - Google Patents

Liganden und deren Verwendung

Info

Publication number
DE3719398C2
DE3719398C2 DE3719398A DE3719398A DE3719398C2 DE 3719398 C2 DE3719398 C2 DE 3719398C2 DE 3719398 A DE3719398 A DE 3719398A DE 3719398 A DE3719398 A DE 3719398A DE 3719398 C2 DE3719398 C2 DE 3719398C2
Authority
DE
Germany
Prior art keywords
cells
ligand
cell
bcgf
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3719398A
Other languages
German (de)
English (en)
Other versions
DE3719398A1 (de
Inventor
Jeffrey A Ledbetter
Edward A Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of DE3719398A1 publication Critical patent/DE3719398A1/de
Application granted granted Critical
Publication of DE3719398C2 publication Critical patent/DE3719398C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE3719398A 1986-06-13 1987-06-11 Liganden und deren Verwendung Expired - Lifetime DE3719398C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (2)

Publication Number Publication Date
DE3719398A1 DE3719398A1 (de) 1988-01-28
DE3719398C2 true DE3719398C2 (de) 1996-03-28

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3719398A Expired - Lifetime DE3719398C2 (de) 1986-06-13 1987-06-11 Liganden und deren Verwendung

Country Status (22)

Country Link
JP (1) JPH0762040B2 (nl)
KR (1) KR910004100B1 (nl)
AT (1) AT398437B (nl)
AU (1) AU617087B2 (nl)
BE (1) BE1000587A4 (nl)
CA (1) CA1338781C (nl)
CH (1) CH676600A5 (nl)
CY (1) CY1681A (nl)
DE (1) DE3719398C2 (nl)
DK (1) DK173940B1 (nl)
FR (1) FR2607136B1 (nl)
GB (1) GB2191494B (nl)
GR (1) GR870930B (nl)
HK (1) HK10293A (nl)
IE (1) IE60486B1 (nl)
IL (1) IL82841A (nl)
IT (1) IT1208649B (nl)
LU (1) LU86919A1 (nl)
NL (1) NL195022C (nl)
PT (1) PT85073B (nl)
SE (1) SE504675C2 (nl)
SG (1) SG118992G (nl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IE871563L (en) 1987-12-13
BE1000587A4 (fr) 1989-02-14
PT85073A (en) 1987-07-01
FR2607136B1 (fr) 1989-09-15
IL82841A0 (en) 1987-12-20
GB8713650D0 (en) 1987-07-15
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
JPH0762040B2 (ja) 1995-07-05
CA1338781C (en) 1996-12-10
AU617087B2 (en) 1991-11-21
SE8702463L (sv) 1987-12-14
JPS6480299A (en) 1989-03-27
AU7421487A (en) 1987-12-17
SE504675C2 (sv) 1997-04-07
IT8720899A0 (it) 1987-06-12
NL8701371A (nl) 1988-01-04
LU86919A1 (fr) 1989-03-08
DE3719398A1 (de) 1988-01-28
KR910004100B1 (ko) 1991-06-22
SG118992G (en) 1993-01-29
IE60486B1 (en) 1994-07-27
GB2191494A (en) 1987-12-16
IL82841A (en) 1992-11-15
AT398437B (de) 1994-12-27
GB2191494B (en) 1990-08-22
IT1208649B (it) 1989-07-10
KR880000582A (ko) 1988-03-28
GR870930B (en) 1987-12-16
PT85073B (pt) 1990-07-31
SE8702463D0 (sv) 1987-06-12
CH676600A5 (nl) 1991-02-15
HK10293A (en) 1993-02-19
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
FR2607136A1 (fr) 1988-05-27
DK302287A (da) 1987-12-14

Similar Documents

Publication Publication Date Title
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69127749T2 (de) Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
DE69727382T2 (de) Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
DE69226431T2 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
Ledbetter et al. Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
DE69509647T2 (de) Agonistische antikörper gegen den flk2/flt3-rezeptor und deren verwendungen
DE3853740T2 (de) Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
DE3751214T2 (de) Monoklonale Antikörper gegen Immunglobulin G Fc-Rezeptoren auf humane mononukleare Phagozyten; bifunktionelle Antikörper; ziel-spezifische Effektorzellen; gezielte Makrophagen und Immunoassays.
US5247069A (en) Ligands and methods for augmenting B-cell proliferation
DE69329503T2 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
DE69100768T2 (de) CD25-bindende Moleküle.
DE69119278T2 (de) Monoklonaler Antikörper, der mit einer neuen HLA-Determinante auf MHC-Klasse-I-Moleküle reagiert, und Verfahren zur Aktivierung von Lymphozyten
DE69329621T2 (de) MONOKLONALE ANTIKöRPER GEGEN DEFINIIERTE REGIONEN DES T-ZELL-ANTIGENREZEPTORS
DE69033631T2 (de) Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
DE4228389C2 (de) Gewinnung und Kultivierung transformierter Zellen
DE69031313T2 (de) Monoklonaler antikörper, der zwischen helfer-inducer- und supressor-inducer-cd4+lymphozyten unterscheidet
DE3687014T2 (de) Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
DE69431526T2 (de) Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
EP0889125B1 (de) Monoklonaler Antikörper 4G8B4B12 gegen humanes FLT3/FLK2
DE3719398C2 (de) Liganden und deren Verwendung
DE69028713T3 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE68914016T2 (de) Identifizierung von NK-Zellen und cytotoxische T-Lymphozyten.
DE69020914T2 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition